"nct_id","nlm_download_date_description","study_first_submitted_date","results_first_submitted_date","disposition_first_submitted_date","last_update_submitted_date","study_first_submitted_qc_date","study_first_posted_date","study_first_posted_date_type","results_first_submitted_qc_date","results_first_posted_date","results_first_posted_date_type","disposition_first_submitted_qc_date","disposition_first_posted_date","disposition_first_posted_date_type","last_update_submitted_qc_date","last_update_posted_date","last_update_posted_date_type","start_month_year","start_date_type","start_date","verification_month_year","verification_date","completion_month_year","completion_date_type","completion_date","primary_completion_month_year","primary_completion_date_type","primary_completion_date","target_duration","study_type","acronym","baseline_population","brief_title","official_title","overall_status","last_known_status","phase","enrollment","enrollment_type","source","limitations_and_caveats","number_of_arms","number_of_groups","why_stopped","has_expanded_access","expanded_access_type_individual","expanded_access_type_intermediate","expanded_access_type_treatment","has_dmc","is_fda_regulated_drug","is_fda_regulated_device","is_unapproved_device","is_ppsd","is_us_export","biospec_retention","biospec_description","ipd_time_frame","ipd_access_criteria","ipd_url","plan_to_share_ipd","plan_to_share_ipd_description","created_at","updated_at","source_class","delayed_posting","expanded_access_nctid","expanded_access_status_for_nctid","fdaaa801_violation","baseline_type_units_analyzed","patient_registry"
"NCT00567528",NA,"2007-12-03",NA,NA,"2015-01-13","2007-12-03","2007-12-05","ESTIMATED",NA,NA,NA,NA,NA,NA,"2015-01-13","2015-01-14","ESTIMATED","2006-05",NA,"2006-05-31","2012-01","2012-01-31","2009-04","ACTUAL","2009-04-30","2009-04","ACTUAL","2009-04-30",NA,"INTERVENTIONAL",NA,NA,"Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes","Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes","TERMINATED",NA,"NA",60,"ACTUAL","Akron Children's Hospital",NA,2,NA,"Study was not producing meaningful data.","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT03071614",NA,"2017-02-13",NA,NA,"2021-02-09","2017-03-01","2017-03-07","ACTUAL",NA,NA,NA,NA,NA,NA,"2021-02-09","2021-02-12","ACTUAL","2019-06","ESTIMATED","2019-06-30","2021-02","2021-02-28","2019-12","ESTIMATED","2019-12-31","2019-12","ESTIMATED","2019-12-31",NA,"INTERVENTIONAL",NA,NA,"Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By English-speaking Population","Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin: A Randomized Controlled Trial Among English-speaking Population","WITHDRAWN",NA,"NA",0,"ACTUAL","Assistance Publique - Hôpitaux de Paris",NA,2,NA,"Lack of funds","f",NA,NA,NA,"f","f","f",NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT02121405",NA,"2014-04-21",NA,NA,"2022-05-05","2014-04-22","2014-04-23","ESTIMATED",NA,NA,NA,NA,NA,NA,"2022-05-05","2022-05-11","ACTUAL","2015-10","ACTUAL","2015-10-31","2022-05","2022-05-31","2026-02","ESTIMATED","2026-02-28","2024-02","ESTIMATED","2024-02-29",NA,"INTERVENTIONAL","PSSR",NA,"Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM","Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy Versus Conventional Preoperative Radiochemotherapy for Locally Advanced Rectal Cancer With MRI Negative Circumferential Margin","SUSPENDED",NA,"PHASE3",350,"ESTIMATED","Zhejiang University",NA,2,NA,"DSMB stopped this trial due to the difference of 3-year DFS's rate between two groups more than 5% at the interim analysis in July 2021.","f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT01693276",NA,"2012-09-19",NA,NA,"2015-10-23","2012-09-21","2012-09-26","ESTIMATED",NA,NA,NA,NA,NA,NA,"2015-10-23","2015-10-26","ESTIMATED","2012-09",NA,"2012-09-30","2015-10","2015-10-31","2014-06","ACTUAL","2014-06-30","2014-06","ACTUAL","2014-06-30",NA,"INTERVENTIONAL",NA,NA,"Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","TERMINATED",NA,"PHASE1/PHASE2",3,"ACTUAL","University of Cincinnati",NA,1,NA,"Slow accrual","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT02115737",NA,"2014-04-14",NA,NA,"2015-11-16","2014-04-14","2014-04-16","ESTIMATED",NA,NA,NA,NA,NA,NA,"2015-11-16","2015-11-17","ESTIMATED","2013-12",NA,"2013-12-31","2015-11","2015-11-30","2014-11","ACTUAL","2014-11-30","2014-11","ACTUAL","2014-11-30",NA,"INTERVENTIONAL",NA,NA,"Group Treatment for Adolescents With Depression","Group Treatment for Adolescents With Depression","TERMINATED",NA,"NA",11,"ACTUAL","Sunnybrook Health Sciences Centre",NA,2,NA,"Insufficient recruitment","f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT02483377",NA,"2015-06-24",NA,NA,"2017-04-18","2015-06-25","2015-06-26","ESTIMATED",NA,NA,NA,NA,NA,NA,"2017-04-18","2017-04-20","ACTUAL","2015-03-05","ACTUAL","2015-03-05","2017-04","2017-04-30","2017-02-07","ACTUAL","2017-02-07","2017-02-07","ACTUAL","2017-02-07",NA,"OBSERVATIONAL",NA,NA,"Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer","Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women","TERMINATED",NA,NA,13,"ACTUAL","University of Southern California",NA,NA,1,"Principal Investigator left","f",NA,NA,NA,"t","f","f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT03436706",NA,"2018-02-10",NA,NA,"2018-04-26","2018-02-10","2018-02-19","ACTUAL",NA,NA,NA,NA,NA,NA,"2018-04-26","2018-04-30","ACTUAL","2019-01","ESTIMATED","2019-01-31","2018-04","2018-04-30","2024-12","ESTIMATED","2024-12-31","2024-12","ESTIMATED","2024-12-31",NA,"OBSERVATIONAL",NA,NA,"Pre-adolescent Stress and Health Study","Pre-adolescent Stress and Health Study","WITHDRAWN",NA,NA,0,"ACTUAL","Penn State University",NA,NA,1,"This study does not qualify as a clinical trial under current NIH guidelines.","f",NA,NA,NA,"f","f","f",NA,NA,NA,NA,NA,NA,NA,NA,"UNDECIDED",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,"f"
"NCT03606980",NA,"2018-06-29","2024-01-04",NA,"2024-02-07","2018-07-23","2018-07-31","ACTUAL","2024-02-07","2024-03-06","ACTUAL",NA,NA,NA,"2024-02-07","2024-03-06","ACTUAL","2018-11-05","ACTUAL","2018-11-05","2024-02","2024-02-29","2023-03-01","ACTUAL","2023-03-01","2021-12-22","ACTUAL","2021-12-22",NA,"INTERVENTIONAL",NA,NA,"Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics","Iontophoresis With Dexamethasone in Combination With Physical Therapy for the Treatment of Pediatric Patients Diagnosed With Apophysitis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial","TERMINATED",NA,"PHASE2",45,"ACTUAL","Children's Health System, Inc.","Our study was limited by limited enrollment, primarily as a result of the COVID-19 pandemic. Slow enrollment following the pandemic led to early closure of the study.",3,NA,"Slow enrollment","f",NA,NA,NA,"f","t","f",NA,NA,"t",NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT04766476",NA,"2021-02-19",NA,NA,"2022-06-08","2021-02-22","2021-02-23","ACTUAL",NA,NA,NA,NA,NA,NA,"2022-06-08","2022-06-09","ACTUAL","2021-02-24","ACTUAL","2021-02-24","2022-06","2022-06-30","2021-08-12","ACTUAL","2021-08-12","2021-08-12","ACTUAL","2021-08-12",NA,"INTERVENTIONAL",NA,NA,"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease","TERMINATED",NA,"PHASE1",9,"ACTUAL","Bristol-Myers Squibb",NA,3,NA,"Business objectives have changed","f",NA,NA,NA,"f","t","f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01235793",NA,"2010-11-05","2018-07-25",NA,"2018-10-23","2010-11-05","2010-11-08","ESTIMATED","2018-10-23","2018-11-20","ACTUAL",NA,NA,NA,"2018-10-23","2018-11-20","ACTUAL","2010-10-14","ACTUAL","2010-10-14","2018-10","2018-10-31","2018-04-18","ACTUAL","2018-04-18","2017-07-28","ACTUAL","2017-07-28",NA,"INTERVENTIONAL","DRBEAT",NA,"The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma","A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma","TERMINATED",NA,"PHASE2",11,"ACTUAL","Cedars-Sinai Medical Center","Enrollment in the clinical trial did not reach the target number of subjects needed to achieve target power and is insufficient to produce statistically reliable results. Clinical trial terminated due to poor enrollment but the outcomes are measured.",1,NA,"The clinical trial was terminated due to poor enrollment","f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT01438151",NA,"2011-09-20","2014-01-06",NA,"2014-03-04","2011-09-20","2011-09-21","ESTIMATED","2014-03-04","2014-04-09","ESTIMATED",NA,NA,NA,"2014-03-04","2014-04-09","ESTIMATED","2011-12",NA,"2011-12-31","2014-03","2014-03-31","2013-12","ACTUAL","2013-12-31","2013-12","ACTUAL","2013-12-31",NA,"INTERVENTIONAL",NA,NA,"Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease","Association of Serum Infliximab and Antibodies Toward Infliximab (ATI) to Clinical Outcomes in Crohn's Disease","TERMINATED",NA,"NA",11,"ACTUAL","Icahn School of Medicine at Mount Sinai","Study was terminated without completion due to poor enrollment.",1,NA,"terminated due to poor enrollment","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT05161533",NA,"2021-12-01",NA,NA,"2023-10-16","2021-12-15","2021-12-17","ACTUAL",NA,NA,NA,NA,NA,NA,"2023-10-16","2023-10-18","ACTUAL","2023-10-19","ESTIMATED","2023-10-19","2023-04","2023-04-30","2024-12-31","ESTIMATED","2024-12-31","2024-10-01","ESTIMATED","2024-10-01",NA,"INTERVENTIONAL",NA,NA,"Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial","CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer","WITHDRAWN",NA,"PHASE2",0,"ACTUAL","University of Washington",NA,1,NA,"Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.","f",NA,NA,NA,"t","t","f",NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT01710683",NA,"2012-10-17",NA,NA,"2015-05-27","2012-10-17","2012-10-19","ESTIMATED",NA,NA,NA,NA,NA,NA,"2015-05-27","2015-05-28","ESTIMATED",NA,NA,NA,"2015-05","2015-05-31",NA,NA,NA,NA,NA,NA,NA,"OBSERVATIONAL",NA,NA,"Early Mobilisation Following Discectomy","Early Mobilisation Following Discectomy","WITHDRAWN",NA,NA,0,"ACTUAL","Northern Orthopaedic Division, Denmark",NA,NA,2,"No participants were enrolled.","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT02461680",NA,"2015-05-27",NA,NA,"2019-08-19","2015-06-02","2015-06-03","ESTIMATED",NA,NA,NA,NA,NA,NA,"2019-08-19","2019-08-21","ACTUAL","2016-02","ACTUAL","2016-02-29","2019-08","2019-08-31","2019-02","ACTUAL","2019-02-28","2019-02","ACTUAL","2019-02-28",NA,"INTERVENTIONAL","FLEXOR",NA,"Treatment for Partial Lesions of the Fingers Flexor Tendons : Tangential Resection or Direct Suture","Management Of The Partial Lesions Of The Fingers Flexor Tendons, Prospective Randomized Trial Of 2 Surgical Procedures: Tangential Resection Versus Direct Suture","TERMINATED",NA,"NA",3,"ACTUAL","University Hospital, Strasbourg, France",NA,2,NA,"recruitment difficulty","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 12:12:25.886051","2024-09-15 12:12:25.886051","OTHER",NA,NA,NA,NA,NA,NA
"NCT04990466",NA,"2021-08-03",NA,NA,"2024-01-17","2021-08-03","2021-08-04","ACTUAL",NA,NA,NA,NA,NA,NA,"2024-01-17","2024-01-19","ACTUAL","2021-09-30","ESTIMATED","2021-09-30","2024-01","2024-01-31","2022-02-28","ESTIMATED","2022-02-28","2021-12-31","ESTIMATED","2021-12-31",NA,"INTERVENTIONAL","BRILIFE002",NA,"Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.","A Phase IIb/3 Randomized, Multi-Center, Placebo-Controlled Noninferiority Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults Compared to an Approved COVID-19 Vaccine","WITHDRAWN",NA,"PHASE2/PHASE3",0,"ACTUAL","NeuroRx, Inc.",NA,2,NA,"Production of the BriLife vaccine was halted by government sponsor","f",NA,NA,NA,"t","f","f",NA,NA,NA,NA,NA,"Protocol, SAP, and ICF will be shared prior to first patient visit. CSR will be shared following regulatory determination","all qualified researchers",NA,"YES","Vaccination dates, baseline serology, and post-vaccination serology/cellular immunity/infection rates will be shared","2024-09-17 00:14:45.348191","2024-09-17 00:14:45.348191","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT00851682",NA,"2009-02-25","2015-09-08",NA,"2018-10-05","2009-02-25","2009-02-26","ESTIMATED","2015-10-14","2015-11-11","ESTIMATED",NA,NA,NA,"2018-10-05","2018-10-31","ACTUAL","2009-01",NA,"2009-01-31","2018-10","2018-10-31","2014-02","ACTUAL","2014-02-28","2014-02","ACTUAL","2014-02-28",NA,"INTERVENTIONAL",NA,NA,"Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma","Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma","TERMINATED",NA,"NA",65,"ACTUAL","Washington University School of Medicine",NA,2,NA,"Enrollment was stopped and will not resume. Participants are no longer being examined.","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT03958669",NA,"2018-12-16",NA,NA,"2024-03-28","2019-05-17","2019-05-22","ACTUAL",NA,NA,NA,NA,NA,NA,"2024-03-28","2024-04-01","ACTUAL","2019-11-01","ACTUAL","2019-11-01","2024-03","2024-03-31","2023-05-31","ACTUAL","2023-05-31","2022-12-31","ACTUAL","2022-12-31",NA,"OBSERVATIONAL","e:Med-HCC-2",NA,"Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC","Prospective Evaluation of Image and Molecular Fingerprint Characterization to Guide Treatment With Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma","TERMINATED",NA,NA,2,"ACTUAL","University Hospital Tuebingen",NA,NA,1,"Slow recruitment due to COVID-19 pandemic and several newly approved treatment options","f",NA,NA,NA,"f","f","f",NA,NA,"f","SAMPLES_WITH_DNA","Tumor Biopsy, Circulating DNA, PBMCs, Circulating Metabolites",NA,NA,NA,"NO",NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,"f"
"NCT04591028",NA,"2020-10-15",NA,NA,"2023-07-17","2020-10-15","2020-10-19","ACTUAL",NA,NA,NA,NA,NA,NA,"2023-07-17","2023-07-19","ACTUAL","2022-01","ESTIMATED","2022-01-31","2023-07","2023-07-31","2022-08-10","ESTIMATED","2022-08-10","2022-01","ESTIMATED","2022-01-31",NA,"INTERVENTIONAL",NA,NA,"A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients","Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer","WITHDRAWN",NA,"PHASE4",0,"ACTUAL","Mayo Clinic",NA,1,NA,"Lack of funding.","f",NA,NA,NA,"f","t","f",NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","OTHER",NA,NA,NA,NA,NA,NA
"NCT02770443",NA,"2016-04-29",NA,NA,"2020-01-21","2016-05-11","2016-05-12","ESTIMATED",NA,NA,NA,NA,NA,NA,"2020-01-21","2020-01-23","ACTUAL","2016-02-19","ACTUAL","2016-02-19","2020-01","2020-01-31","2019-11","ACTUAL","2019-11-30","2017-08-24","ACTUAL","2017-08-24",NA,"INTERVENTIONAL","WrecEF",NA,"Withdrawal of Medication in Recovered DCM","Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.","TERMINATED",NA,"NA",22,"ACTUAL","McGill University",NA,2,NA,"Study closed to recruitment early as endpoints were reached on several participants","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT00791336",NA,"2008-11-13","2017-03-09",NA,"2017-06-29","2008-11-13","2008-11-14","ESTIMATED","2017-06-29","2017-07-28","ACTUAL",NA,NA,NA,"2017-06-29","2017-07-28","ACTUAL","2008-08",NA,"2008-08-31","2017-06","2017-06-30","2011-03","ACTUAL","2011-03-31","2011-03","ACTUAL","2011-03-31",NA,"INTERVENTIONAL",NA,NA,"Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer","A Phase II Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients With Stage III Non Small Cell Lung Cancer","TERMINATED",NA,"PHASE2",1,"ACTUAL","University of Iowa","There was only one treated participant. Conclusions cannot be drawn from these data due to limited sampling size.",1,NA,"Poor enrollment.","f",NA,NA,NA,"t","t","f",NA,NA,"f",NA,NA,NA,NA,NA,"NO","Terminated due to poor enrollment; lack of data to share.","2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","OTHER",NA,NA,NA,NA,NA,NA
"NCT06080165",NA,"2023-09-29",NA,NA,"2024-07-08","2023-10-05","2023-10-12","ACTUAL",NA,NA,NA,NA,NA,NA,"2024-07-08","2024-07-10","ACTUAL","2024-07","ESTIMATED","2024-07-31","2024-07","2024-07-31","2028-06","ESTIMATED","2028-06-30","2028-06","ESTIMATED","2028-06-30",NA,"INTERVENTIONAL",NA,NA,"Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations","A Randomized Controlled Double-Blind Trial of Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations","WITHDRAWN",NA,"PHASE1/PHASE2",0,"ACTUAL","Stanford University",NA,2,NA,"Investigator decided not to proceed with the trial.","f",NA,NA,NA,"t","t","f",NA,NA,"f",NA,NA,"shared twice per year",NA,"https://nda.nih.gov/","YES","Data will be on the National Institute of Mental Health Data Archive (NDA).","2024-09-15 12:12:25.886051","2024-09-15 12:12:25.886051","OTHER",NA,NA,NA,NA,NA,NA
"NCT00243828",NA,"2005-10-24",NA,NA,"2015-09-14","2005-10-24","2005-10-25","ESTIMATED",NA,NA,NA,NA,NA,NA,"2015-09-14","2015-09-15","ESTIMATED","2005-11",NA,"2005-11-30","2007-03","2007-03-31","2007-12","ACTUAL","2007-12-31","2007-09","ACTUAL","2007-09-30",NA,"INTERVENTIONAL",NA,NA,"Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure","Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure: a Randomized Controlled Trial.","TERMINATED",NA,"PHASE4",300,NA,"Corporacion Parc Tauli",NA,NA,NA,"Very low rate of recruitment anticipated futility of pursuing the study","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:55:15.80435","2024-09-16 11:55:15.80435","OTHER",NA,NA,NA,NA,NA,NA
"NCT04120610",NA,"2019-10-07",NA,NA,"2023-01-09","2019-10-07","2019-10-09","ACTUAL",NA,NA,NA,NA,NA,NA,"2023-01-09","2023-01-11","ACTUAL","2019-12-09","ACTUAL","2019-12-09","2023-01","2023-01-31","2022-11-21","ACTUAL","2022-11-21","2022-11-21","ACTUAL","2022-11-21","6 Months","OBSERVATIONAL",NA,NA,"FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia","FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI)","TERMINATED",NA,NA,196,"ACTUAL","Medtronic Endovascular",NA,NA,2,"Sponsor decision to terminate study prior to reaching full sample size.","f",NA,NA,NA,"f","f","t",NA,NA,"f",NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","INDUSTRY",NA,NA,NA,NA,NA,"t"
"NCT03897062",NA,"2019-03-26",NA,NA,"2023-02-13","2019-03-29","2019-04-01","ACTUAL",NA,NA,NA,NA,NA,NA,"2023-02-13","2023-02-15","ACTUAL","2019-08-26","ACTUAL","2019-08-26","2023-02","2023-02-28","2022-07-31","ACTUAL","2022-07-31","2022-07-31","ACTUAL","2022-07-31",NA,"INTERVENTIONAL",NA,NA,"Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence","A Placebo-controlled, Double -Blind Randomised Trial of Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence","TERMINATED",NA,"PHASE2",22,"ACTUAL","The Florey Institute of Neuroscience and Mental Health",NA,2,NA,"Recruitment problems during covid lockdowns resulted in Merck ceasing supply of suvorexant/placebo","f",NA,NA,NA,"t","t","f",NA,NA,"t",NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","OTHER",NA,NA,NA,NA,NA,NA
"NCT01410695",NA,"2011-08-04",NA,"2018-12-12","2018-12-13","2011-08-04","2011-08-05","ESTIMATED",NA,NA,NA,"2018-12-13","2018-12-17","ACTUAL","2018-12-13","2018-12-17","ACTUAL","2011-07",NA,"2011-07-31","2018-12","2018-12-31","2015-10","ACTUAL","2015-10-31","2015-10","ACTUAL","2015-10-31",NA,"INTERVENTIONAL",NA,NA,"Masitinib in Refractory Active Rheumatoid Arthritis","A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs","TERMINATED",NA,"PHASE2/PHASE3",324,"ACTUAL","AB Science",NA,3,NA,"Sponsor decision based on portfolio prioritization","f",NA,NA,NA,"t","t","f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT03429374",NA,"2018-01-09",NA,NA,"2021-05-20","2018-02-05","2018-02-12","ACTUAL",NA,NA,NA,NA,NA,NA,"2021-05-20","2021-05-24","ACTUAL","2018-11-19","ACTUAL","2018-11-19","2021-05","2021-05-31","2021-05-20","ACTUAL","2021-05-20","2021-05-20","ACTUAL","2021-05-20",NA,"INTERVENTIONAL",NA,NA,"Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width","Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width: a Multicenter Randomized Controlled Study","TERMINATED",NA,"NA",16,"ACTUAL","Duomed",NA,2,NA,"Limited patient enrollment","f",NA,NA,NA,NA,"f","f",NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01289938",NA,"2011-02-02",NA,NA,"2016-05-12","2011-02-03","2011-02-04","ESTIMATED",NA,NA,NA,NA,NA,NA,"2016-05-12","2016-05-13","ESTIMATED","2009-07",NA,"2009-07-31","2016-05","2016-05-31","2015-06","ACTUAL","2015-06-30","2015-06","ACTUAL","2015-06-30",NA,"INTERVENTIONAL","MalD",NA,"Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine","Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine","TERMINATED",NA,"PHASE1",49,"ACTUAL","University Hospital Tuebingen",NA,2,NA,"To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT01237340",NA,"2010-11-05","2012-09-11",NA,"2013-08-04","2010-11-08","2010-11-09","ESTIMATED","2012-09-11","2012-10-11","ESTIMATED",NA,NA,NA,"2013-08-04","2013-08-07","ESTIMATED","2010-10",NA,"2010-10-31","2013-08","2013-08-31","2011-12","ACTUAL","2011-12-31","2011-12","ACTUAL","2011-12-31",NA,"INTERVENTIONAL",NA,NA,"Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study","A Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD)","TERMINATED",NA,"PHASE3",59,"ACTUAL","EMD Serono",NA,1,NA,"The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical Practice (GCP) requirements was not ensured - No safety concerns","f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 22:59:40.430939","2024-09-16 22:59:40.430939","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01741376",NA,"2012-11-30",NA,NA,"2019-09-03","2012-11-30","2012-12-04","ESTIMATED",NA,NA,NA,NA,NA,NA,"2019-09-03","2019-09-06","ACTUAL","2012-11","ACTUAL","2012-11-30","2019-09","2019-09-30","2012-11","ACTUAL","2012-11-30","2012-11","ACTUAL","2012-11-30",NA,"INTERVENTIONAL",NA,NA,"Progesterone and Atomoxetine for Cocaine Cessation","Progesterone and Atomoxetine for Cocaine Cessation","WITHDRAWN",NA,"NA",0,"ACTUAL","University of Minnesota",NA,2,NA,"All clinical trials within the Department of Psychiatry at UMN were suspended and this study was withdrawn due to no enrollment.","f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","OTHER",NA,NA,NA,NA,NA,NA
